Fulgent Genetics, a technology company that focuses on genetic testing, completed the acquisition of Fulgent Pharma, an independent clinical-stage, therapeutics development company focused on the development of innovative cancer treatments, for $100m. “This acquisition advances our mission to build a holistic platform to provide comprehensive solutions and services across the cancer care continuum, including early detection, diagnostics, and monitoring, as well as drug discovery and development. With my commitment and our teams already in place, the combination of these two businesses diversifies our assets and will, we believe, provide sustainable future revenue and margin opportunity through a potentially lucrative target oncology market," Ming Hsieh, Fulgent Genetics Chairman and CEO.